Ontario Teachers Pension Plan Board Cuts Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Ontario Teachers Pension Plan Board reduced its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 49.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,967 shares of the specialty pharmaceutical company’s stock after selling 14,782 shares during the period. Ontario Teachers Pension Plan Board’s holdings in Jazz Pharmaceuticals were worth $1,802,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of JAZZ. Kovack Advisors Inc. raised its stake in Jazz Pharmaceuticals by 88.8% in the first quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock worth $6,816,000 after buying an additional 26,628 shares in the last quarter. Baupost Group LLC MA lifted its holdings in shares of Jazz Pharmaceuticals by 23.7% during the fourth quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock valued at $102,545,000 after purchasing an additional 160,000 shares during the last quarter. Polaris Capital Management LLC lifted its holdings in shares of Jazz Pharmaceuticals by 2.2% during the fourth quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock valued at $155,898,000 after purchasing an additional 27,100 shares during the last quarter. John G Ullman & Associates Inc. purchased a new position in Jazz Pharmaceuticals in the 1st quarter worth approximately $3,631,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $380,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on JAZZ shares. Barclays decreased their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Friday, May 3rd. StockNews.com lowered shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, July 5th. Morgan Stanley decreased their price objective on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a report on Friday, July 12th. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They issued a “buy” rating and a $169.00 target price for the company. Finally, UBS Group cut their target price on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a research report on Tuesday, July 2nd. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $185.86.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the transaction, the executive vice president now owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 4.20% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock traded down $0.82 during mid-day trading on Tuesday, reaching $108.88. 10,056 shares of the company’s stock traded hands, compared to its average volume of 674,231. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $146.70. The firm has a 50 day moving average price of $107.28 and a two-hundred day moving average price of $114.69. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. The firm has a market capitalization of $6.87 billion, a PE ratio of 22.62, a price-to-earnings-growth ratio of 1.68 and a beta of 0.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). The firm had revenue of $901.98 million during the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. On average, research analysts forecast that Jazz Pharmaceuticals plc will post 15.32 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.